Teleflex Incorporated (NYSE:TFX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Teleflex Incorporated (NYSE:TFX) have been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $259.25.

TFX has been the subject of several recent analyst reports. Mizuho dropped their target price on Teleflex from $275.00 to $250.00 and set a “neutral” rating for the company in a research report on Friday, November 1st. Stephens upped their price objective on Teleflex from $275.00 to $290.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Royal Bank of Canada decreased their target price on Teleflex from $275.00 to $245.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Truist Financial restated a “hold” rating and issued a $227.00 price target (down from $255.00) on shares of Teleflex in a report on Monday, November 4th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Teleflex in a report on Friday, November 1st.

Hedge Funds Weigh In On Teleflex

A number of large investors have recently bought and sold shares of TFX. Tidal Investments LLC boosted its holdings in shares of Teleflex by 214.7% in the 1st quarter. Tidal Investments LLC now owns 6,644 shares of the medical technology company’s stock valued at $1,503,000 after buying an additional 4,533 shares in the last quarter. Comerica Bank grew its holdings in Teleflex by 13.0% in the first quarter. Comerica Bank now owns 14,491 shares of the medical technology company’s stock worth $3,277,000 after purchasing an additional 1,662 shares during the last quarter. Swedbank AB acquired a new position in shares of Teleflex during the first quarter worth $679,000. Boston Partners lifted its holdings in shares of Teleflex by 105.9% during the 1st quarter. Boston Partners now owns 2,831 shares of the medical technology company’s stock valued at $640,000 after purchasing an additional 1,456 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale grew its stake in shares of Teleflex by 2.5% during the first quarter. DekaBank Deutsche Girozentrale now owns 7,290 shares of the medical technology company’s stock worth $1,606,000 after acquiring an additional 180 shares during the last quarter. Institutional investors own 95.62% of the company’s stock.

Teleflex Stock Up 0.6 %

NYSE TFX opened at $193.08 on Friday. Teleflex has a 12 month low of $185.66 and a 12 month high of $257.85. The company has a current ratio of 2.42, a quick ratio of 1.39 and a debt-to-equity ratio of 0.37. The stock has a market cap of $8.97 billion, a PE ratio of 38.39, a P/E/G ratio of 1.96 and a beta of 1.18. The stock’s 50 day moving average is $219.90 and its 200 day moving average is $222.34.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, October 31st. The medical technology company reported $3.49 earnings per share for the quarter, topping the consensus estimate of $3.38 by $0.11. The company had revenue of $764.40 million for the quarter, compared to analysts’ expectations of $768.68 million. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. Teleflex’s quarterly revenue was up 2.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.64 earnings per share. Research analysts predict that Teleflex will post 13.98 EPS for the current fiscal year.

Teleflex Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Friday, November 15th will be given a $0.34 dividend. The ex-dividend date is Friday, November 15th. This represents a $1.36 annualized dividend and a dividend yield of 0.70%. Teleflex’s payout ratio is presently 27.04%.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.